AMPS therapy start-up Gondola awarded a CHF 500,000 Tech Growth loan

Specializing in AMPS therapy allowing people with neurological disease to move better and live better, Gondola Medical Technologies was awarded a CHF 500,000 Tech Growth loan from the the Foundation for Technological Innovation.

Founded in 2011, Gondola Medical Technologies specializes the development of new technologies in the field of neurorehabilitation to improve the quality of life of patients affected by neurological disorders such as stroke, Parkinson’s and ataxia.

The AMPS (Automated Mechanical Peripheral Stimulation) treatment provided by the Gondola medical device is a cutting-edge, non-invasive and non-pharmacological approach that helps to improve movement disorders.

Clinical research and studies have demonstrated Gondola AMPS therapy’s effectiveness, which allowed Gondola Medical Technologies to earn a Tech Growth loan in the amount of CHF 500,000. This funding will be dedicated to research and development, which includes growing the start-ups clinical research team and studies.

Clinical expertise and research in a world leading research hub for life sciences companies

In 2014, Gondola Medical Technologies was awarded the StartCup price as the most innovative company in Ticino. Since 2019, it raised a total of EUR 4 million (equity and loans), including a EUR 2.5 million grant from the EU Horizon 2020 research and innovation program, and a first installment of CHF 200,000 from the Fondation pour l’Innovation Technologique (FIT).

The company’s headquarters are located at the Biopôle science park in Lausanne (canton of Vaud), one of the world’s top research hubs for companies specialized in life sciences.